Clinical Trials Logo

Recurrent Ovarian Carcinosarcoma clinical trials

View clinical trials related to Recurrent Ovarian Carcinosarcoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05920798 Recruiting - Clinical trials for Recurrent Ovarian Carcinoma

A Study of FRaDCs for Ovarian Cancer

Start date: September 28, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the response rate to the combination of folate receptor alpha dendritic cells (FRaDCs) plus pembrolizumab in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. Vaccines made from a person's peptide treated white blood cells may help the body build an effective immune response to kill tumor cells.

NCT ID: NCT04092270 Recruiting - Clinical trials for Recurrent Ovarian Carcinoma

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Start date: May 7, 2020
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of peposertib when given together with pegylated liposomal doxorubicin hydrochloride in treating patients with high or low grade ovarian cancer that has come back after a period of improvement (recurrent). Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving peposertib and pegylated liposomal doxorubicin hydrochloride may work better in treating patients with ovarian cancer compared to pegylated liposomal doxorubicin hydrochloride alone.